In a study completed at the University of Sassari in Italy, physicians addressed post-menopausal pelvic floor changes such as stress urinary incontinence (UI), urogenital atrophy, and recurrent urinary tract infections. Half of the 206 post-menopausal women in this study were treated with intravaginal estriol (1 mg treatment daily for 2 weeks then 2 treatments/week for a total of 6 months). The other half was treated with estriol in addition to pelvic floor rehabilitation.
The outcomes measured at beginning and 6 months after start of treatment included urine cultures, urogenital symptomatology, and urethral pressure profiles, among other measures. At 6 months, urogenital atrophy was improved in both treatment groups. While in the control group (estriol only) patients reported a 9.71% improvement in urinary incontinence, 73.49% of the patients who were treated with estriol plus pelvic floor rehabilitation reported improvements in UI. Urethral closure pressures were also significantly improved in the estriol plus rehab group.
The authors conclude that pelvic floor rehabilitation in addition to estriol should be considered as first-line therapy for symptoms of urogenital aging in postmenopausal women.